text: <unk>  is an antineoplastic agent and mitotic Inhibitor that is FDA approved for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting..   Common adverse reactions include alopecia, weight loss, constipation, anorexia, nausea, anemia, neutropenia, ALT/SGPT elevation, arthralgia, myalgia, asthenia, headache, peripheral neuropathy, fatigue, fever..
option_0: Eribulin
option_1: Myelin
option_2: Dynactin
option_3: Cycasin
option_4: Erdosteine
option_5: Retapamulin
option_6: Vytorin
option_7: Acrinathrin